{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:22:09Z","timestamp":1740126129857,"version":"3.37.3"},"reference-count":26,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Dermatol"],"DOI":"10.1111\/bjd.17991","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T22:27:01Z","timestamp":1555021621000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Continued treatment with secukinumab is associated with high retention or regain of response"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"M.","family":"Augustin","sequence":"first","affiliation":[{"name":"Institute of Health Services Research in Dermatology and Nursing University Medical Center of Hamburg Eppendorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Thaci","sequence":"additional","affiliation":[{"name":"Comprehensive Centre of Inflammation Medicine University of L\u00fcbeck L\u00fcbeck Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Eyerich","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Technical University of Munich Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pinter","sequence":"additional","affiliation":[{"name":"University Hospital Frankfurt Frankfurt am Main Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Radtke","sequence":"additional","affiliation":[{"name":"Institute of Health Services Research in Dermatology and Nursing University Medical Center of Hamburg Eppendorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Lauffer","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Technical University of Munich Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Mrowietz","sequence":"additional","affiliation":[{"name":"Psoriasis\u2010Center Department of Dermatology University Medical Center Schleswig\u2010Holstein Kiel Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gerdes","sequence":"additional","affiliation":[{"name":"Psoriasis\u2010Center Department of Dermatology University Medical Center Schleswig\u2010Holstein Kiel Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Pariser","sequence":"additional","affiliation":[{"name":"Eastern Virginia Medical School and Virginia Clinical Research, Inc. Norfolk VA U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Department of Dermatology Icahn School of Medicine at Mount Sinai New York U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Sieder","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH N\u00fcrnberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Melzer","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH N\u00fcrnberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-4332","authenticated-orcid":false,"given":"K.","family":"Reich","sequence":"additional","affiliation":[{"name":"Dermatologikum Berlin and SCIderm Research Institute Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,7,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jdv.12817","article-title":"PASI90 response: the new standard in therapeutic efficacy for psoriasis","volume":"29","author":"Puig L","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_6_3_1","first-page":"S3","article-title":"The role of IL\u201017 in the pathogenesis and treatment of psoriasis","volume":"9","author":"Zeichner JA","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2013 results of two phase 3 trials","volume":"371","author":"Langley RG","year":"2014","journal-title":"NEJM"},{"key":"e_1_2_6_5_1","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti\u2010interleukin\u201017A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double\u2010blind, placebo\u2010controlled trial","volume":"382","author":"Baeten D","year":"2013","journal-title":"Lancet"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti\u2010interleukin\u201017A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double\u2010blind, placebo\u2010controlled, phase 3 trial","volume":"386","author":"McInnes IB","year":"2015","journal-title":"Lancet"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Thaci D","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate\u2010to\u2010severe plaque psoriasis up to 1 year: results from the CLEAR study","volume":"76","author":"Blauvelt A","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favorable safety profile in patients with moderate to severe psoriasis through 5 years of treatment (SCULPTURE extension study)","volume":"32","author":"Bissonnette R","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.12788\/j.sder.2016.022","article-title":"Why biologic therapies sometimes lose efficacy","volume":"35","author":"Strober BE","year":"2016","journal-title":"Semin Cutan Med Surg"},{"key":"e_1_2_6_11_1","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jaad.2017.11.036","article-title":"Drug survival of secukinumab in real\u2010world plaque psoriasis patients: a 52\u2010week, multicenter, retrospective study","volume":"78","author":"Georgakopoulos JR","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_12_1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei PL","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"volume-title":"Itch: Mechanisms and Treatment","year":"2014","author":"Reich A","key":"e_1_2_6_13_1"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.jaad.2016.05.049","article-title":"Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks","volume":"75","author":"Huang YYM","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13555-018-0220-y","article-title":"Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab","volume":"8","author":"Spindeldreher S","year":"2018","journal-title":"Dermatol Ther"},{"key":"e_1_2_6_16_1","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/bjd.14965","article-title":"Secukinumab, a fully human anti\u2010interleukin\u201017A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate\u2010to\u2010severe plaque psoriasis","volume":"176","author":"Reich K","year":"2017","journal-title":"Br J Dermatol"},{"key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: a systematic review and meta\u2010analysis of observational studies","volume":"2","author":"Armstrong AW","year":"2012","journal-title":"Nutr Diabetes"},{"key":"e_1_2_6_18_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1346-8138.2011.01408.x","article-title":"Psoriasis and metabolic syndrome","volume":"39","author":"Takahashi H","year":"2012","journal-title":"J Dermatol"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti\u2010tumor necrosis factor\u2010alpha agents in patients with select immune\u2010mediated inflammatory diseases: a systematic review and meta\u2010analysis","volume":"13","author":"Singh S","year":"2018","journal-title":"PLOS ONE"},{"key":"e_1_2_6_20_1","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00403-014-1495-1","article-title":"Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients","volume":"306","author":"Yanaba K","year":"2014","journal-title":"Arch Dermatol Res"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","article-title":"Primary non\u2010response to tumor necrosis factor antagonists is associated with inferior response to second\u2010line biologics in patients with inflammatory bowel diseases: a systematic review and meta\u2010analysis","volume":"12","author":"Singh S","year":"2018","journal-title":"J Crohns Colitis"},{"key":"e_1_2_6_22_1","first-page":"320","article-title":"Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate\u2010to\u2010severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE\u20102 and AMAGINE\u20103","volume":"179","author":"Papp KA","year":"2018","journal-title":"Br J Dermat"},{"key":"e_1_2_6_23_1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jaad.2013.08.042","article-title":"Research gaps in psoriasis: opportunities for future studies","volume":"70","author":"Ryan C","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_24_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-4632.2004.01828.x","article-title":"Seasonal variation of dermatologic disease in the USA: a study of office visits from 1990 to 1998","volume":"43","author":"Hancox JG","year":"2004","journal-title":"Int J Dermatol"},{"key":"e_1_2_6_25_1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/jdv.12210","article-title":"Factors influencing seasonal patterns of relapse in anti\u2010TNF psoriatic responders after temporary drug discontinuation","volume":"28","author":"Ruano J","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_6_26_1","first-page":"788","article-title":"Throat infections are associated with exacerbation in a substantial proportion of patients with chronic plaque psoriasis","volume":"96","author":"Thorleifsdottir RH","year":"2016","journal-title":"Acta Derm Venereo"},{"key":"e_1_2_6_27_1","unstructured":"Tha\u00e7iD.Secukinumab real\u2010world effectiveness data on plaque psoriasis treatment in Germany corroborate pivotal clinical trial results: analysis of the first 2 000 subjects enrolled in the PROSPECT study. In:27th EADV Congress Paris 2018 Vol. P1994."}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.17991","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.17991","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.17991","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.17991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:48:54Z","timestamp":1676382534000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/182\/1\/67\/6731385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,17]]},"references-count":26,"alternative-id":["10.1111\/bjd.17991"],"URL":"https:\/\/doi.org\/10.1111\/bjd.17991","archive":["Portico"],"relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"type":"print","value":"0007-0963"},{"type":"electronic","value":"1365-2133"}],"subject":[],"published":{"date-parts":[[2019,7,17]]},"assertion":[{"value":"2019-04-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bjd.17991"}}